By SPC News Staff
Multiple sites of the Epstein-Barr virus (EBV) appear to be vulnerable. A panel of investigational monoclonal antibodies (mAbs) targeting these different sites blocked infection in human cells in vitro.
Moreover, one of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in mice (Immunity 2022 Oct 27. https://doi.org/10.1016/j.immuni.2022.10.003).
The researchers developed several investigational mAbs targeting two